Skip Navigation


Rheumatology Advance Access originally published online on February 3, 2005
Rheumatology 2005 44(4):465-468; doi:10.1093/rheumatology/keh494
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/4/465    most recent
keh494v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Durez, P.
Right arrow Articles by Westhovens, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Durez, P.
Right arrow Articles by Westhovens, R.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 4 © British Society for Rheumatology 2005; all rights reserved

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study

P. Durez, F. Van den Bosch1, L. Corluy2, E. M. Veys1, L. De Clerck3, A. Peretz4, M. Malaise5, J.-P. Devogelaer, N. Vastesaeger6, A. Geldhof7 and R. Westhovens2

Rheumatology Departments, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1 University Hospital R. U. Ghent, 2 University Hospitals K. U. Leuven, 3 University Hospital Antwerp, University of Antwerp, 4 University Hospital Brugmann, Brussels, 5 University Hospital Liège, 6 Schering Plough, Belgium, 7 Centocor BV, Leiden, Belgium.

Corresponding author: R. Westhovens, Rheumatology Department, UZ Gasthuisberg, Katholieke Universiteit Leuven, Belgium. E-mail: rene.westhovens{at}uz.kuleuven.ac.be

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks.

Methods. Patients suffering from active refractory RA despite methotrexate, were treated with i.v. infusions of infliximab (3 mg/kg) on week 0, 2, 6 and every 8 weeks thereafter. Based on the clinical judgement at week 22, patients received a dose increase of 100 mg from week 30 on. The American College of Rheumatology (ACR) core set for disease activity measures was regularly assessed.

Results. Five hundred and eleven RA patients were included. At week 22, 61.4, 34 and 14.1% of all patients met ACR 20, ACR 50 and ACR 70 criteria, respectively, and 6.1% of patients were in remission. A low swollen joint count at baseline was correlated with improvement at week 22 for ACR 20 (P<0.06), ACR 50 (P<0.06) and ACR 70 (P<0.005). The change in HAQ score between weeks 0 and 22 was predictive for response at week 54 (P<0.01). The dose of infliximab was increased by 100 mg in 22% of the patients. Most baseline values of patients requiring dose increase were higher (P ≤ 0.001) than the baseline values of the remaining patients. Increasing the dose of infliximab by one vial from week 30 on could circumvent the partial loss of response in these patients.

Conclusion. Infliximab use in this large out-patient cohort resulted in a significant clinical improvement. A subgroup that partially lost response during the first 22 weeks could regain response by adding 100 mg of infliximab to the subsequent doses. Due to the current study design, however, a regression to the mean like effect could not be ruled out.

KEY WORDS: Rheumatoid arthritis, Infliximab, Dose adjustment, ACR core set


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. E. Kristensen, P. Geborek, and T. Saxne
Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register
Rheumatology, March 1, 2009; 48(3): 243 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
B J F van den Bemt, A A den Broeder, G F Snijders, Y A Hekster, P L C M van Riel, B Benraad, G J Wolbink, and F H J van den Hoogen
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
Ann Rheum Dis, December 1, 2008; 67(12): 1697 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Ariza-Ariza, F. Navarro-Sarabia, B. Hernandez-Cruz, L. Rodriguez-Arboleya, V. Navarro-Compan, and J. Toyos
Dose escalation of the anti-TNF-{alpha} agents in patients with rheumatoid arthritis. A systematic review
Rheumatology, March 1, 2007; 46(3): 529 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. Durez, F. Van den Bosch, L. Corluy, E. Veys, L. De Clerck, A. Peretz, M. Malaise, J.-P. Devogelaer, N. Vastesaeger, A. Geldhof, et al.
Timing of DAS28 in infliximab therapy: reply
Rheumatology, September 1, 2005; 44(9): 1204 - 1204.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. J. Armstrong and I. N. Bruce
Timing of DAS28 in infliximab therapy
Rheumatology, September 1, 2005; 44(9): 1203 - 1204.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.